Labrycor (Isoprenaline Hydrochloride)

Isoprenaline Hydrochloride is a non‑selective beta‑adrenergic agonist. It binds to β1 receptors in the heart and β2 receptors in the lungs and vasculature, activating adenylate cyclase, increasing cAMP, and thereby enhancing heart rate, myocardial force of contraction, and bronchodilation.

The specific dose of Labrycor is determined by the prescribing clinician based on the patient’s condition, weight, and response. Dosage regimens are individualized and should follow the prescriber’s orders and institutional protocols.

Safety data for Isoprenaline Hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Labrycor, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Labrycor (Isoprenaline) is a non‑selective beta‑agonist, providing both β1 and β2 stimulation, whereas agents like Dobutamine are more β1‑selective. Isoprenaline offers stronger bronchodilatory effects, making it useful for asthma, but it may cause more tachycardia compared with more cardio‑selective alternatives.

Labrycor should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from direct light, moisture, and extreme temperatures. Do not freeze the product, and inspect the vial for particulate matter before use.

Labrycor is administered by intravenous infusion under continuous clinical supervision. The solution is typically diluted in a compatible carrier fluid and infused at a rate prescribed by the treating physician, with vital signs monitored throughout the administration.

Serious risks include life‑threatening arrhythmias, myocardial ischemia, severe hypotension, and allergic reactions such as anaphylaxis. Immediate medical attention is required if any of these events occur during or after infusion.

Labrycor is contraindicated in patients with known hypersensitivity to Isoprenaline, uncontrolled ventricular tachyarrhythmias, recent myocardial infarction, severe aortic stenosis, or uncontrolled hypertension. Clinicians should assess each patient’s medical history before initiating therapy.